Objective: The aim of this study was to verify if six months of isoflavone supplementation could increase fat-free mass (FFM) and muscle mass index (MMI ¼ appendicular FFM/height 2 ) in obese-sarcopenic postmenopausal women. Design: Double-blind randomized study. Subject: Eighteen sarcopenic-obese women completed the study (12 on isoflavones and six on placebo). Body composition was measured by dual-energy X-ray absorptiometry. Subjects ingested 70 mg of isoflavones per day (44 mg of diadzein, 16 mg glycitein and 10 mg genestein) or a placebo for 24 weeks. Results: The isoflavone group increased significantly appendicular (P ¼ 0.034), leg (P ¼ 0.016) FFM and MMI (P ¼ 0.037), but not the placebo group. Conclusion: Six months of isoflavone supplementation increased FFM and MMI in obese-sarcopenic postmenopausal women.
Introduction
Menopause is associated with a decrease in muscle mass, also known as sarcopenia (Beaufrere and Morio, 2000) , which is significantly associated with functional limitations and physical disability (Tanko et al., 2002) . Hormonal replacement therapy (HRT) has been shown to promote the maintenance or increase total fat-free mass (FFM) (Haarbo et al., 1991; Greeves et al., 1999; Skelton et al., 1999) . As such, estrogens may have a direct effect on muscle via its estrogen receptors (Lemoine et al., 2003) . However, the Women's Health Initiative study revealed that estrogens combined with progesterone increased cardiovascular morbidity and mortality risks in postmenopausal women (Rossouw et al., 2002) . Hence, the use of HRT has thus become controversial. In contrast, phytoestrogens are structurally comparable to 17b-estradiol that have shown estrogenic properties (Hsu et al., 2001; van der Schouw et al., 2005) . Metabolic studies have found that soy, which contains isoflavones, exerts a lipid-lowering effect (Hermansen et al., 2001) , favours vasodilatation and arterial compliance (Walker et al., 2001) and contributes to regulate fasting glucose and insulin levels in humans (Crisafulli et al., 2005) . In addition, phytoestrogens by their estrogenic properties may favourably affect muscle mass. Nevertheless, it is unknown if isoflavone supplementation could increase FFM. The aim of this study was to verify if 6 months of isoflavone supplementation could increase FFM in obese-sarcopenic postmenopausal women compared to a placebo.
Methods

Subjects
Fifty postmenopausal women aged between 50 and 70 years (5875 years) were recruited for a larger trial by the use of advertisements in local newspaper. To be included in the trial, women had to meet the following criteria: overweight or obese (body mass index 428 kg/m 2 and waist circumference 488 cm), healthy, without major physical incapacity, without HRT (women had never been on HRT or off HRT for at least 1 year), sedentary, weight stable (72 kg) for the last 6 months, non-smoker, moderate drinker (15 g of alcohol/day maximum, the equivalent of one alcoholic beverage/day), no medication that could influence glucose or lipid metabolism and absence of menses for the past 12 months. A phone interview was conducted to screen for the aforementioned inclusion criteria. After subjects were thoroughly explained of the nature and goals of the study, they provided written informed consent. Women were randomly assigned to one of two groups (isoflavone (ISO) vs placebo (PLA)) to compare the effect of 6 months of isoflavone supplementation on body composition and cardiovascular disease risk factors. Subjects received either four soy capsules or four identical placebo capsules daily for 6 months in a double-blind fashion. Each capsule contained 325 mg of soy extract with 17.5 mg of isoflavones (total dose of isoflavones was 70 mg/day which was divided into 44 mg of diadzein, 16 mg glycitein and 10 mg genestein). Identical active and placebo capsules were supplied by Arkopharma Ltd (France). To be included in this analysis, all subjects had to be sarcopenic and obese. Sarcopenia was defined as a muscle mass index (MMI) o6.87 kg appendicular FFM/m 2 and obesity as a fat mass (FM) 440% (Baumgartner et al., 2004) . At baseline, among the 50 women, 24 were considered sarcopenic-obese (14 on ISO vs 10 on PLA), of whom 18 completed the study (12 on ISO vs 6 on PLA) and constitute the women included in the present study. The percentage of withdrawal (25%) is in accordance with the literature (Fox et al., 1996) . The reasons for dropping out were personal reasons or lack of time (two in ISO vs four in PLA). None reported adverse effect to the treatment. All procedures were approved by the Ethics Committee of the Geriatric Institute of University of Sherbrooke.
Body composition measurements Overall. Body weight was determined by using an electronic scale (kg70.2; SECA707, Hambourg, Germany). Height was measured using a tape measure fixed to the wall with the subject in stocking feet. Determination of FM and FFM was assessed in a supine position, by the use of dual-energy X-ray absorptiometry (GE Prodigy Lunar, Madison, WI, USA). In our laboratory, the coefficients of variations for repeated measures of FM and FFM in 10 adults (measured 1 week apart) are 0.9 and 0.4%, respectively (Aubertin- Leheudre et al., 2005) . FFM is herein defined as the mass of tissue representing soft tissue exclusively (mineral body mass excluded).
Muscle mass index MMI is generally used as an index of sarcopenia and is calculated as follows:
Class I sarcopenia is considered as a MMI between one or more standard deviations below the values of young adults from a reference population (Baumgartner et al., 1998; Janssen et al., 2002) . In our laboratory, women were considered sarcopenic when MMI was o6.87 appendicular FFM kg/m 2 . These criteria were established based on a reference sample of 30 healthy women aged between 20 and 35 years.
Statistical analyses
Results are presented as means7s.d. A one-way analysis of variance was used to verify the difference between groups at baseline and at 6 months. Furthermore, a paired t-test was performed to verify the difference in each group between the measures at baseline and at 6 months. Finally, an analysis of covariance (Univariate General linear model) was used to verify the effect of the isoflavone treatment after 6 months on body composition. P-values of p0.05 were considered statistically significant. Analyses were performed using SPSS 11.0 program (Chicago, IL, USA).
Results
No difference was found at baseline and at 6 months between groups for all variables (Table 1) . We observed a significant difference for the isoflavone group between baseline and 6 months for appendicular FFM (P ¼ 0.006) and MMI (P ¼ 0.002), but not in the placebo group. Moreover, we observed a significant treatment effect of isoflavone supplementation on appendicular (P ¼ 0.016), leg (P ¼ 0.034) FFM and MMI (P ¼ 0.037).
Discussion
The aim of this study was to examine if 6 months of isoflavone supplementation could increase FFM in obesesarcopenic postmenopausal women compared to a placebo. Our results demonstrated that 6 months of isoflavone supplementation has a beneficial effect on FFM and MMI in obese-sarcopenic postmenopausal women and specifically on appendicular FFM which is recognized to be responsible for locomotion and physical independence (Sowers et al., 2005) . One explanation about this effect could be that skeletal muscle is an important site of estrogen receptors a (ERa) and -b (ERb) and that phytoestrogens are known to have estrogenic properties. In this sense, it has been demonstrated previously that soy protein supplementation has an effect on hip lean mass in perimenopausal women 40 g/day for 24weeks (Moeller et al., 2003) ; and on lean body mass in elite athletes, 1.5 g/kg/day for 8 weeks (Dragan et al., 1992) . However, our study supports the fact that this effect was not solely because of an increase in dietary protein intake but likely to the beneficial effect of isoflavones on muscle tissue. As such, our results are concordant with those of Wu et al. (2004) , who found a significant increase in FFM in ovariectomized mice after an isoflavone supplementation. Hence, although the increase in FFM that was observed was not sufficient to counteract sarcopenia totally, further research is needed to understand by which mechanism isoflavone supplementation could influence FFM metabolism and if a greater duration of intervention could counteract sarcopenia.
